Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia
Authors
Keywords
-
Journal
Future Oncology
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2019-05-29
DOI
10.2217/fon-2018-0881
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial
- (2019) Loretta J Nastoupil et al. Lancet Haematology
- Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study
- (2018) Howard A Burris et al. LANCET ONCOLOGY
- Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration
- (2018) Ahmed Y. Ali et al. LEUKEMIA
- Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a Phase 1 study
- (2018) Susan O'Brien et al. AMERICAN JOURNAL OF HEMATOLOGY
- Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper
- (2018) Antonio Cuneo et al. HEMATOLOGICAL ONCOLOGY
- The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies
- (2018) Kerrie Faia et al. PLoS One
- DUO delivers for duvelisib
- (2018) Jennifer R. Brown BLOOD
- The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
- (2018) Ian W. Flinn et al. BLOOD
- Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study
- (2018) Matthew S Davids et al. Lancet Haematology
- B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia
- (2017) Hima V. Vangapandu et al. MOLECULAR CANCER RESEARCH
- Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment
- (2016) Elisa ten Hacken et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
- (2016) Changchun Deng et al. BLOOD
- Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
- (2016) Jacqueline C Barrientos Future Oncology
- Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
- (2016) V M Patel et al. LEUKEMIA
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- PI3Kγ is a molecular switch that controls immune suppression
- (2016) Megan M. Kaneda et al. NATURE
- p84 forms a negative regulatory complex with p110γ to control PI3Kγ signalling during cell migration
- (2015) Michelle E Turvey et al. IMMUNOLOGY AND CELL BIOLOGY
- Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase δ but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells
- (2015) Kathleen J. Till et al. JOURNAL OF IMMUNOLOGY
- The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL
- (2015) K Balakrishnan et al. LEUKEMIA
- How to treat old MCL patients: one size fits it all?
- (2014) M. Dreyling et al. BLOOD
- IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells
- (2014) S. Dong et al. BLOOD
- Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
- (2014) Khaled Ali et al. NATURE
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
- (2013) David G. Winkler et al. CHEMISTRY & BIOLOGY
- p87 and p101 Subunits Are Distinct Regulators Determining Class IBPhosphoinositide 3-Kinase (PI3K) Specificity
- (2013) Aliaksei Shymanets et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Molecular determinants of PI3K -mediated activation downstream of G-protein-coupled receptors (GPCRs)
- (2013) O. Vadas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
- (2013) Jan A. Burger et al. SEMINARS IN CANCER BIOLOGY
- B-cell receptor signaling in chronic lymphocytic leukemia
- (2011) F. K. Stevenson et al. BLOOD
- CAL-101, a p110 selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
- (2010) B. J. Lannutti et al. BLOOD
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- The microenvironment in mature B-cell malignancies: a target for new treatment strategies
- (2009) J. A. Burger et al. BLOOD
- Molecular and cellular mechanisms of CLL: novel therapeutic approaches
- (2009) Lisa Pleyer et al. Nature Reviews Clinical Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation